Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FIX-GMAC
- Development stage
- Preclinical
- Lead developer
- CellGenTech
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Implant
01
Overview
FIX-GMAC (also known as HB-GMAC) is an investigational autologous cell and gene therapy being developed by CellGenTech for the treatment of hemophilia B. The therapy utilizes CellGenTech's Genetically Modified Adipocytes (GMAC) platform, where pre-adipocytes are isolated from a patient's own subcutaneous fat tissue and genetically modified ex vivo using a viral vector to express the normal human coagulation factor IX (FIX) gene. Once implanted back into the patient, these modified adipocytes are intended to continuously secrete functional factor IX, providing a sustained, long-term source of the clotting factor to prevent bleeding episodes. FIX-GMAC is currently in the feasibility and pre-preclinical stages of development.
Beyond the preview
Go deeper on FIX-GMAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FIX-GMAC.